Can peptides cause cancer?

This is the question people are most afraid to ask about peptides, and it deserves a straight answer instead of either false reassurance or scare tactics. The honest picture has three distinct parts: one FDA-approved peptide with a real, documented warning; a category of unapproved peptides with a legitimate but unproven theoretical concern; and a supply chain problem that's a separate issue entirely. We'll take them one at a time.

The one FDA-approved peptide with an actual cancer warning

Semaglutide, the peptide behind Ozempic and Wegovy, is the clearest, most documented case. Its FDA-approved prescribing information, as summarized by the National Institutes of Health's MedlinePlus, states plainly:

"Semaglutide injection may increase the risk that you will develop thyroid gland tumors, including a type of thyroid cancer. Semaglutide injection caused thyroid tumors in rats. It is not known if this medication increases the risk of tumors in humans."

— FDA-approved prescribing information, via MedlinePlus, U.S. National Library of Medicine (NIH)

This is worth sitting with for a moment, because it's an unusually specific and honest label: the tumor finding is in rats, not confirmed in humans, and the drug is still FDA-approved because regulators judged its benefits (for diabetes and obesity, which carry their own serious health risks) to outweigh that unresolved risk for most patients. People with a personal or family history of certain thyroid cancers or Multiple Endocrine Neoplasia syndrome type 2 (MEN 2) are specifically told not to take it.¹

This matters for the wider peptide question because the American Medical Association reports the same theme from a treating physician. Dr. Anthony C. Tam, a family and sports medicine physician with Henry Ford Health, told the AMA that certain patients "such as those with specific types of endocrine cancers" should avoid GLP-1 peptide medications like semaglutide, and that doctors have well-established guidelines for who is and isn't a good candidate.² In other words: this isn't a fringe concern. It's a mainstream, monitored one, built into how physicians prescribe an FDA-approved peptide.

What large human studies have found

Because the FDA boxed warning rests on animal data, the key question is what studies of actual people have found. The human evidence — now spanning hundreds of thousands of patients — is more reassuring than the label alone suggests, though it isn't fully settled.

A 2024 cohort study across Denmark, Norway, and Sweden, published in the British Medical Journal, followed approximately 145,000 patients on GLP-1 receptor agonists and found no significant increase in thyroid cancer risk compared to people on other diabetes medications over nearly four years of follow-up. Researchers noted one important constraint: medullary thyroid carcinoma — the specific cancer subtype raised in the rodent findings — is rare enough in human populations that even large cohorts often don't generate enough events to study it in isolation.⁵

A separate systematic review pooling 10 randomized controlled trials with 14,550 participants found thyroid cancer incidence in semaglutide-treated patients was below 1%, with the authors concluding this result excluded the hypothesis of carcinogenesis. These findings don't close the question permanently — thyroid cancer can develop slowly enough that a four-year observation window may miss a late-emerging signal — but they do shift the evidence considerably toward reassurance for patients without MTC or MEN2 history.

The theoretical concern with growth-hormone-boosting peptides

A separate group of popular wellness peptides, including CJC-1295, ipamorelin, sermorelin, and various growth-hormone-releasing peptides (GHRPs), work by raising the body's own growth hormone or growth-factor signaling. This is where a real but genuinely theoretical concern comes in: growth-signaling pathways are, by their nature, involved in cell growth, and that's the same broad biological territory in which semaglutide's rat thyroid-tumor finding showed up.

The important word is theoretical. No published human trial has found that these specific unapproved peptides raise cancer risk, but no published human trial has ruled it out either, because those trials, at the scale that would answer the question, haven't been run. This is exactly the kind of gap that led the FDA to place BPC-157 on its list of bulk substances that raise safety concerns for compounding, citing "insufficient data to evaluate its safety."³ The same absence-of-data problem applies across most of this newer generation of wellness peptides.

What about the supply chain?

Separate from the biological question is the sourcing question. Most wellness peptides sold online carry a "research use only" label, meaning there's no requirement they contain what the label says, at the purity it claims, free of contaminants. That's a real and serious risk, covered in full on our are peptides safe page, but it's a different risk from a specific cancer link. Even a peptide that turns out to carry zero cancer risk can still hurt you if the vial is contaminated or the dose is wrong.

What to actually do with this information

• Tell any prescribing doctor your full personal and family cancer history before starting any peptide, especially GLP-1 medications or anything that raises growth hormone.
• Don't take reassurance from "it's natural" or "it's just amino acids." The concern here is about biological pathway, not chemical origin.
• Go through a licensed physician, not a self-sourced vial, so the people prescribing know your history and can watch for warning signs like a lump or swelling in the neck, which MedlinePlus flags as a symptom to report immediately with semaglutide.¹

For the full picture on any specific compound, see our BPC-157 research breakdown and do peptides work pages, and talk to a doctor about your specific history before starting anything.